Swecure, a research and development stage biotechnology company primarily focused on developing novel treatments for immunoregulatory diseases such as allergy, IBD and IBS, receives patent approval grant by the US Patent and Trademark Office. The invention relates to a use of bacterial superantigens for the prevention of allergy in children as well as a method for the prevention of inflammatory disorders.
The patent, which has previously been approved in Europe, forms the basis for one of Swecure's four ongoing developments: Swe01, which is the company's lead candidate and the world's first preventive treatment for allergies. Currently a double-blinded proof-of-concept study in dogs is being conducted from which the results are expected to be analyzed in early 2016.
"This US patent approval complements the earlier European approval and further enhances Swecure's proprietary position," said Lars Fahlén, CEO of Swecure AB. "We are convinced that Swe01 will meet a significant need in the medical market and the approved patents will allow us to protect our technology as we continue our research and product development."
The Swe01 has already attracted interest from collaboration partners such as Astma & Allergiförbundet (The Swedish Asthma & Allergy Association) and from potential international industry partners.
Swe01 is based on 15 years of global clinical research. A cohort study made by the research team showed that infants that were colonized in the gut by S. aureus were protected from developing food allergy. Indications from the cohort study have been confirmed in mice models as well as in new born puppies; those treated with superantigen showed an early immune activation compared to controls